Which donor or graft source should you choose for the strongest GVL? Is there really any difference

Daniel Weisdorf

doi:10.1016/j.beha.2013.10.010

Which donor or graft source should you choose for the strongest GVL? Is there really any difference

Daniel Weisdorf

Medicine - Hematology, Oncology, Transplant

Research output: Contribution to journal › Review article › peer-review

8 Scopus citations

Abstract

Patients undergoing allogeneic hematopoietic cell transplantation (HCT) face relapse of their malignancy as the most frequent cause of treatment failure. It has been postulated that the allogeneic neoplastic potency of different donor or graft sources may differ and in some situations, a particular graft source might be preferred. Data on this supposition has been reviewed here to consider HLA-matched siblings, HLA-matched or partially matched unrelated donors (URD), unrelated umbilical cord blood (UCB), and haploidentical as well as blood or marrow grafts.

Original language	English (US)
Pages (from-to)	293-296
Number of pages	4
Journal	Best Practice and Research: Clinical Haematology
Volume	26
Issue number	3
DOIs	https://doi.org/10.1016/j.beha.2013.10.010
State	Published - Sep 2013

Keywords

GVL, graft-versus-leukemia
HCT hematopoietic cell transplantation
HLA-matched donors
UCB, umbilical cord blood
bone marrow
graft source
haploidentical
peripheral blood
relapse

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1016/j.beha.2013.10.010

OpenUrl availability

Full text

Cite this

@article{b090b6ccc5904d3bbcab081718b8251d,

title = "Which donor or graft source should you choose for the strongest GVL? Is there really any difference",

abstract = "Patients undergoing allogeneic hematopoietic cell transplantation (HCT) face relapse of their malignancy as the most frequent cause of treatment failure. It has been postulated that the allogeneic neoplastic potency of different donor or graft sources may differ and in some situations, a particular graft source might be preferred. Data on this supposition has been reviewed here to consider HLA-matched siblings, HLA-matched or partially matched unrelated donors (URD), unrelated umbilical cord blood (UCB), and haploidentical as well as blood or marrow grafts.",

keywords = "GVL, graft-versus-leukemia, HCT hematopoietic cell transplantation, HLA-matched donors, UCB, umbilical cord blood, bone marrow, graft source, haploidentical, peripheral blood, relapse",

author = "Daniel Weisdorf",

year = "2013",

month = sep,

doi = "10.1016/j.beha.2013.10.010",

language = "English (US)",

volume = "26",

pages = "293--296",

journal = "Best Practice and Research: Clinical Haematology",

issn = "1521-6926",

publisher = "Bailliere Tindall Ltd",

number = "3",

}

TY - JOUR

T1 - Which donor or graft source should you choose for the strongest GVL? Is there really any difference

AU - Weisdorf, Daniel

PY - 2013/9

Y1 - 2013/9

N2 - Patients undergoing allogeneic hematopoietic cell transplantation (HCT) face relapse of their malignancy as the most frequent cause of treatment failure. It has been postulated that the allogeneic neoplastic potency of different donor or graft sources may differ and in some situations, a particular graft source might be preferred. Data on this supposition has been reviewed here to consider HLA-matched siblings, HLA-matched or partially matched unrelated donors (URD), unrelated umbilical cord blood (UCB), and haploidentical as well as blood or marrow grafts.

AB - Patients undergoing allogeneic hematopoietic cell transplantation (HCT) face relapse of their malignancy as the most frequent cause of treatment failure. It has been postulated that the allogeneic neoplastic potency of different donor or graft sources may differ and in some situations, a particular graft source might be preferred. Data on this supposition has been reviewed here to consider HLA-matched siblings, HLA-matched or partially matched unrelated donors (URD), unrelated umbilical cord blood (UCB), and haploidentical as well as blood or marrow grafts.

KW - GVL, graft-versus-leukemia

KW - HCT hematopoietic cell transplantation

KW - HLA-matched donors

KW - UCB, umbilical cord blood

KW - bone marrow

KW - graft source

KW - haploidentical

KW - peripheral blood

KW - relapse

UR - http://www.scopus.com/inward/record.url?scp=84889659302&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84889659302&partnerID=8YFLogxK

U2 - 10.1016/j.beha.2013.10.010

DO - 10.1016/j.beha.2013.10.010

M3 - Review article

C2 - 24309533

AN - SCOPUS:84889659302

SN - 1521-6926

VL - 26

SP - 293

EP - 296

JO - Best Practice and Research: Clinical Haematology

JF - Best Practice and Research: Clinical Haematology

IS - 3

ER -

Which donor or graft source should you choose for the strongest GVL? Is there really any difference

Abstract

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this